Table 1.

Univariate and multivariate cox proportional hazard analysis for overall survival and recurrence free survival in GC patients.

	Univariate analysis			Multivariate analysis
Variable	HR	95%CI	P-value	HR	95%CI	P-value
OS (n = 167)
Age ≥ 69	2.85	1.62–5.21	0.0002	3.72	1.84–7.86	0.0002
Male	1.67	0.91–3.32	0.1
Macroscopic type 3 or 4	5.46	3.11–9.98	<0.0001	1.79	0.81–4.12	0.15
Tumour size >35 mm	2.95	1.64–5.64	0.0002	1.12	0.51–2.48	0.78
Poorly differentiated histology	1.55	0.90–2.70	0.11
T Stage greater than T4	7.06	3.97–13.13	<0.0001	1.83	0.78–4.45	0.17
Lymph node metastasis positive	8.35	4.15–19.17	<0.0001	4.26	1.54–13.67	0.004
Lymphatic invasion positive	4.3	1.99–11.24	<0.0001	0.45	0.12–1.65	0.22
Venous invasion positive	4.05	2.32–7.32	<0.0001	0.63	0.27–1.43	0.27
Hepatic metastasis positive	16.85	6.63–37.59	<0.0001	6.17	2.30–14.93	0.0007
Peritoneal metastasis positive	7.67	3.89–14.19	<0.0001	2.05	0.92–4.46	0.08
Distant metastasis positive	6.04	2.99–11.34	<0.0001	6.57	2.64–16.27	<0.0001
Combined m6A panel high risk	5.21	2.97–9.42	<0.0001	2.24	1.15–4.49	0.02
RFS (n = 138)
Age ≥69	2.48	1.07–6.16	0.03	1.14	0.40–3.40	0.81
Male	1.28	0.55–3.33	0.58
Macroscopic type 3 or 4	5.57	2.44–13.4	<0.0001	0.95	0.35–2.75	0.92
Tumour size >35 mm	4.68	1.87–14.19	0.0007	3.11	1.05–10.66	0.04
Poorly differentiated histology	4.1	1.63–12.41	0.002	1.41	0.48–4.87	0.55
T Stage greater than T4	12.79	5.29–35.54	<0.0001	2.07	0.63–7.58	0.24
Lymph node metastasis positive	19.79	5.79–123.84	<0.0001	4.49	0.76–45.57	0.1
Lymphatic invasion positive	14.29	3.00–255.91	<0.0001	1.47	0.14–34.10	0.76
Venous invasion positive	5.34	2.31–13.28	<0.0001	1.52	0.51–4.71	0.46
Combined m6A panel high risk	11.62	4.81–31.32	<0.0001	6.46	2.21–21.00	0.0005

HR hazard ratio, CI confidence interval.

Bold indicates a statistically significant.